ROE
58.4%
✅ ROE 58.4% clears the 15% quality threshold; stability over 3–5 years is not available in this feed.
NYSE · Information Technology · Small Cap · Mkt cap $179.4B · Vol 17.57M
$40.70
▲ +0.00% today
Live · market · updated 10:06:58 PM
Day $40.23–$40.96 · 52w $35.12–$64.16
Research Novo Nordisk A/S (NYSE: NVO) using available valuation, profitability and leverage data. Check each figure's source and compare reporting periods before drawing conclusions. Missing provider data must not be treated as a reported company fact.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Source: Yahoo Finance — Novo Nordisk A/S company profileCompany website
Available ratios are snapshots. This page does not provide a complete historical quarterly-results, profit-and-loss, balance-sheet or shareholding series. Use company filings to verify reporting periods, accounting changes and trends.
Weighted 13-factor score / 100
Novo Nordisk A/S scores 79/100 on the DeepScreen quality-and-value model. Growth is running near 5.6% with a PEG of 4.33, ROCE of 32.2% and debt/equity at 0.62x. Valuation and capital efficiency line up favourably against sector norms.
Vision & Utility score and Secret Tips badges is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Target price, trim level & stop-loss is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
The 79/100 score is a weighted average of 13 fundamental factors. This panel shows which factor scores contribute most to the current model result.
Cheap vs. earnings. Weighted contribution: 7.8 points.
Modest sales multiple. Weighted contribution: 5.5 points.
Low for an asset-light business. Weighted contribution: 6.3 points.
Low for asset-light. Weighted contribution: 9.4 points.
Overvalued vs. growth. Weighted contribution: 0.6 points.
Good upside gearing. Weighted contribution: 2.8 points.
Strong for asset-light. Weighted contribution: 4.4 points.
Moderate long-term leverage. Weighted contribution: 4.9 points.
Factor scores are model outputs, not forecasts. A high or low factor score describes how that metric is treated by the DeepScreen rules; review the underlying value and its source before drawing a broader conclusion.
Current operating, capital-efficiency and cash-flow metrics using the latest available provider data.
Provider-reported period-over-period growth
Provider-reported period-over-period growth
Return on equity
Return on capital employed
Net income as a share of revenue
Debt relative to shareholder equity
26% of operating cash flow
Cash $46.35B · Debt $134.48B
Provider periods can differ by field. Growth figures are presented as reported by the upstream provider; they are not reconstructed from an expensive historical time series.
Threshold-based research checks from the latest available fundamentals. These are on-page signals, not push notifications or predictions.
ROE and ROCE both above 15% (58.4% / 32.2%) — genuine capital efficiency, not just debt-flattered equity returns.
Signals are intended to highlight questions for research, not replace company filings or independent review.
Industry match: Drug Manufacturers - General. Peers use the same regional market universe, same sector, provider-reported industry where available, and market-cap proximity.
Peer fundamentals are still loading. The comparison will populate automatically when comparable company data arrives.
DeepScreen Secret Tips, traps & X-Ray analysis is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.
Piotroski F-Score
7/87
7 of 8 financial-health checks passed (1 checks need data this provider doesn't publish).
Altman Z-Score
Insufficient data—
Needs total assets, operating profit and debt — not published for this listing yet.
Beneish (earnings quality)
Low distortion risk1.13
Accrual-quality check only: operating cash flow is 113% of reported net profit. Below 80% means profits aren't fully backed by cash.
Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.
P/E Ratio (TTM)
Live10.3x
Cheap vs. earnings
Price divided by earnings per share: how much you pay today for ₹1/$1 of annual profit. Only compare within the same industry.
PEG Ratio
LivePro
Advanced ratio · DeepScreen Pro
Pro
P/S Ratio
Live0.54x
Modest sales multiple
Price relative to revenue. Sales are much harder to accounting-fudge than earnings, so this is a trustworthy number — and it's often the only usable multiple for loss-making or early-stage companies where P/E doesn't exist. But revenue without margin means nothing on its own: always read it alongside net margin.
P/B Ratio
Live5.48x
Typical for the sector
Price versus net asset value. Asset-light businesses like this one carry most of their value in people and IP, not machinery or property, so P/B runs structurally high here — not a red flag by itself. Weigh P/E and ROE more heavily instead.
EV/Revenue
LivePro
Advanced ratio · DeepScreen Pro
Pro
EV/EBITDA
LivePro
Advanced ratio · DeepScreen Pro
Pro
ROE
Live58.4%
Excellent shareholder returns
Return on shareholder equity. High ROE is great — unless it is manufactured by heavy debt, so always read it next to ROA and D/E: high ROE with low ROA is the classic debt-trap pattern.
ROA
Live19.1%
Strong for asset-light
Net Income / Total Assets — how efficiently the whole business converts its asset base into profit. Computed as ROE / (1 + D/E) when live data is unavailable. Only compare within the same industry: asset-light businesses (IT, services) will always show a structurally higher ROA than asset-heavy ones (steel, airlines, utilities) simply because they carry far less on the balance sheet to begin with, not because they're better run.
ROCE
Modeled32.2%
High-quality compounder
Return on all capital employed (equity plus debt). The cleanest quality signal because debt cannot flatter it.
Debt / Equity
Live0.62x
Manageable
Total liabilities divided by shareholders' equity — the broadest leverage measure. High leverage boosts ROE in good years and destroys it in bad ones.
LT Debt / Equity
ModeledPro
Advanced ratio · DeepScreen Pro
Pro
Payout Ratio
Live45%
Ideal balance — sustainable with room to reinvest
Share of profit paid out as dividend. Above 100% means the company is funding the dividend from debt or reserves, not profit — a genuine red flag, not just 'high'. 30–60% is the classic sustainable balance; well below that usually just means a growth company reinvesting rather than anything wrong.
Operating Leverage
Modeled1.60x
Good upside gearing
How much profit jumps for each 1% of extra sales — driven by how much of the cost base is fixed (rent, salaries) versus variable (raw materials). It's a double-edged sword: high fixed-cost businesses (manufacturing, airlines, software) see profit jump disproportionately as sales grow, but the same fixed costs turn a small sales dip into an outsized loss. That's also why these businesses tend to lead in a bull market and get hit hardest first when demand turns down.
DCF & Graham intrinsic value calculators is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Figures use live Yahoo Finance data where available; any field Yahoo doesn't report falls back to the DeepScreen model.
Loading live headlines…
Review the scoring factors, underlying data and limitations before comparing companies.
Read the methodology